Daniel S. Lorrain - Nov 18, 2024 Form 4 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Signature
/s/ Peter Slover, Attorney-in-Fact
Stock symbol
CTNM
Transactions as of
Nov 18, 2024
Transactions value $
-$101,421
Form type
4
Date filed
11/20/2024, 05:07 PM
Previous filing
May 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTNM Class A Common Stock Sale -$99.7K -6.09K -3.47% $16.37 170K Nov 18, 2024 Direct F1, F2
transaction CTNM Class A Common Stock Sale -$1.69K -99 -0.06% $17.05 170K Nov 18, 2024 Direct F1
holding CTNM Class A Common Stock 3.9K Nov 18, 2024 By Spouse F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on August 19, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.03 to $17.02, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3 Includes 325 shares purchased through Issuer's Employee Stock Purchase Plan.